In wake of Eli Lilly setback, Merck KGaA's leading BTK drug for autoimmune disease clears PhIIb hurdle
What kind of future awaits Bruton’s tyrosine kinase drugs in autoimmune conditions?
A familiar player in hematology, which attracted the first big round of investment for BTK drugs like ibrutinib that can hit back at abnormal B cells, researchers have been exploring uncharted avenues of drug development for autoimmune diseases. And the potential leader in the field, Merck KGaA’s evobrutinib, just cleared a big hurdle in the clinic that just might lay the foundation for a pivotal effort around multiple sclerosis.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.